New In Vivo Syngeneic Glioblastoma Mouse Model Shuttle Session

05 / 23 / 2018

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-June, 2018. In this session, only experimental test groups-related costs will be covered by Sponsors ; control groups being supported by Explicyte.

Our validated syngeneic glioma mouse model is based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring. Model responsiveness to standard Temozolomide (TMZ) and immune checkpoint inhibitors (ICI) i.e. anti-CTLA4 and anti-PD1 antibodies (Figures 1 & 2), makes it well-suited for chemo- and immunotherapy assessment and for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.

Contact us to reserve your seat & test your compound(s).

Figure 1. Orthotopic syngeneic GL261 glioblastoma model is responsive to TMZ and checkpoint inhibitors. Mice were OT implanted with GL261-Luc2 glioma cells and then treated with either TMZ, anti-PD1, or anti-CTLA4 antibodies, or with respective vehicles. Survival was monitored overtime.

Figure 3. Intracranial glioma tumor-bearing model is characterized by tumorinfiltrating immune cells. (A) Hematoxylin-associated immunohistochemistry staining of GL261 glioma-bearing mouse brain sections (a) shows the presence of F4/80+ macrophages (b) and of CD8+ cytotoxic lymphocytes infiltrating the tumor (c). Presence of tumor-infiltrating PD1-expressing immune cells is highlighted in (d). (B) Flow cytometry profiling of GL261 tumor shows high infiltration by myeloid CD45+ CD11b+ cells. MDSCs CD11b+ are identified as granulocytic (Gr1High) or monocytic (Gr1Low) (left plot). Further analysis within CD11b+ cell populations demonstrated (right plot) presence of myeloid Ly6G+ Ly6CInt and Ly6G+ Ly6CLow populations, which are known to harbor immunosuppressive properties and thus to participate in the tumor immune escape. 

Shuttle for efficacy assessment on 6-week experimental session

  • Model / Strain: GL261-Luc2 glioblastoma / C57BL/6 mice
  • Readouts: Tumor growth (Bioluminescence imaging) / Body weight / Survival
  • Standard reference(s): TMZ, PD1 or CTLA4 monoclonal antibodies – to be discussed with the Sponsor
  • Group size: At least 10 mice per group

Optional analyses: Satellite studies for immune response profiling and MoA delineation (flow cytometry, RT-qPCR, immunohistochemistry…). Contact us for further information.